ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: CML patients develop resistance to nilotinib or imatinib by acquiring kinase domain mutations in ABL1 (e.g. gatekeeper mutation, T315I), which renders the protein insensitive to the drugs50.